<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Anticoagulant Reversal, Blood Pressure Levels, and Anticoagulant Resumption in Patients With Anticoagulation-Related Intracerebral Hemorrhage</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date>05/17/2022</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Joji</forename><forename type="middle">B</forename><surname>Kuramatsu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Stefan</forename><forename type="middle">T</forename><surname>Gerner</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Peter</forename><forename type="middle">D</forename><surname>Schellinger</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Jörg</forename><surname>Glahn</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Matthias</forename><surname>Endres</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Jan</forename><surname>Sobesky</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Julia</forename><surname>Flechsenhar</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Hermann</forename><surname>Neugebauer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Eric</forename><surname>Jüttler</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Armin</forename><surname>Grau</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Frederick</forename><surname>Palm</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Joachim</forename><surname>Röther</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Peter</forename><surname>Michels</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Gerhard</forename><forename type="middle">F</forename><surname>Hamann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Joachim</forename><surname>Hüwel</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Georg</forename><surname>Hagemann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Beatrice</forename><surname>Barber</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Christoph</forename><surname>Terborg</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Frank</forename><surname>Trostdorf</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Hansjörg</forename><surname>Bäzner</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Aletta</forename><surname>Roth</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Johannes</forename><surname>Wöhrle</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Moritz</forename><surname>Keller</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Michael</forename><surname>Schwarz</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Gernot</forename><surname>Reimann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Jens</forename><surname>Volkmann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Wolfgang</forename><surname>Müllges</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Peter</forename><surname>Kraft</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Joseph</forename><surname>Classen</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Carsten</forename><surname>Hobohm</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Markus</forename><surname>Horn</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Angelika</forename><surname>Milewski</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Heinz</forename><surname>Reichmann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Hauke</forename><surname>Schneider</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Eik</forename><surname>Schimmel</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Gereon</forename><forename type="middle">R</forename><surname>Fink</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD;</roleName><forename type="first">Christian</forename><surname>Dohmen</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Henning</forename><surname>Stetefeld</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Otto</forename><surname>Witte</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Albrecht</forename><surname>Günther</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Tobias</forename><surname>Neumann-Haefelin</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Andras</forename><forename type="middle">E</forename><surname>Racs</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Martin</forename><surname>Nueckel</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Frank</forename><surname>Erbguth</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Stephan</forename><forename type="middle">P</forename><surname>Kloska</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Arnd</forename><surname>Dörfler</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Martin</forename><surname>Köhrmann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Stefan</forename><surname>Schwab</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Hagen</forename><forename type="middle">B</forename><surname>Huttner</surname></persName>
							<email>hagen.huttner@uk-erlangen.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<addrLine>Schwabachanlage 6</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Anticoagulant Reversal, Blood Pressure Levels, and Anticoagulant Resumption in Patients With Anticoagulation-Related Intracerebral Hemorrhage</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published">05/17/2022</date>
						</imprint>
					</monogr>
					<idno type="MD5">1E7931E71EFB98775F80A33EB3E4D789</idno>
					<idno type="DOI">10.1001/jama.2015.0846</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:32+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IMPORTANCE</head><p><s>Although use of oral anticoagulants (OACs) is increasing, there is a substantial lack of data on how to treat OAC-associated intracerebral hemorrhage (ICH).</s></p><p><s>OBJECTIVE To assess the association of anticoagulation reversal and blood pressure (BP) with hematoma enlargement and the effects of OAC resumption.</s><s>DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study at 19 German tertiary care centers (2006-2012) including 1176 individuals for analysis of long-term functional outcome, 853 for analysis of hematoma enlargement, and 719 for analysis of OAC resumption.</s><s>EXPOSURES Reversal of anticoagulation during acute phase, systolic BP at 4 hours, and reinitiation of OAC for long-term treatment.</s><s>MAIN OUTCOMES AND MEASURES Frequency of hematoma enlargement in relation to international normalized ratio (INR) and BP.</s><s>Incidence analysis of ischemic and hemorrhagic events with or without OAC resumption.</s><s>Factors associated with favorable (modified Rankin Scale score, 0-3) vs unfavorable functional outcome.</s><s>RESULTS Hemorrhage enlargement occurred in 307 of 853 patients (36.0%).</s><s>Reduced rates of hematoma enlargement were associated with reversal of INR levels &lt;1.3 within 4 hours after admission (43/217 [19.8%]) vs INR of Ն1.3 (264/636 [41.5%];</s><s>P &lt; .001)</s><s>and systolic BP &lt;160 mm Hg at 4 hours (167/504 [33.1%]) vs Ն160 mm Hg (98/187 [52.4%];</s><s>P &lt; .001).</s><s>The combination of INR reversal &lt;1.3 within 4 hours and systolic BP of &lt;160 mm Hg at 4 hours was associated with lower rates of hematoma enlargement (35/193 [18.1%] vs 220/498 [44.2%] not achieving these values; OR, 0.28; 95% CI, 0.19-0.42;</s><s>P &lt; .001)</s><s>and lower rates of in-hospital mortality (26/193 [13.5%] vs 103/498 [20.7%];</s><s>OR, 0.60; 95% CI, 0.37-0.95;</s><s>P = .03).</s><s>OAC was resumed in 172 of 719 survivors (23.9%).</s><s>OAC resumption showed fewer ischemic complications (OAC: 9/172 [5.2%] vs no OAC: 82/547 [15.0%];</s><s>P &lt; .001)</s><s>and not significantly different hemorrhagic complications (OAC: 14/172 [8.1%] vs no OAC: 36/547 [6.6%]; P = .48).</s><s>Propensity-matched survival analysis in patients with atrial fibrillation who restarted OAC showed a decreased HR of 0.258 (95% CI, 0.125-0.534;</s><s>P &lt; .001)</s><s>for long-term mortality.</s><s>Functional long-term outcome was unfavorable in 786 of 1083 patients (72.6%).</s></p><p><s>CONCLUSIONS AND RELEVANCE Among patients with OAC-associated ICH, reversal of INR &lt;1.3 within 4 hours and systolic BP &lt;160 mm Hg at 4 hours were associated with lower rates of hematoma enlargement, and resumption of OAC therapy was associated with lower risk of ischemic events.</s><s>These findings require replication and assessment in prospective studies.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>T he prevalence of cardiovascular diseases requiring long-term oral anticoagulation (OAC) is increasing, notably the incidence and prevalence of atrial fibrillation. <ref type="bibr">1,</ref><ref type="bibr" target="#b3">2</ref></s><s>The most significant complication of OAC is intracerebral hemorrhage (ICH). <ref type="bibr" target="#b4">3</ref></s><s>]<ref type="bibr" target="#b7">[6]</ref><ref type="bibr" target="#b8">[7]</ref> Among all stroke subtypes is a substantial lack of data about how to manage OAC-ICH. <ref type="bibr" target="#b9">8</ref></s><s>Current European Stroke Organisation guidelines, World Stroke Organization reviews, and American Heart Association Stroke Council recommendations only provide Level C evidence and Class II recommendations regarding treatment of OAC-ICH. <ref type="bibr" target="#b4">3,</ref><ref type="bibr" target="#b10">9,</ref><ref type="bibr" target="#b11">10</ref></s><s>Two of the most pressing unsettled questions are how to prevent hematoma enlargement and how to manage anticoagulation in the long-term. <ref type="bibr" target="#b9">8,</ref><ref type="bibr" target="#b12">11</ref></s><s>Consensus exists that elevated international normalized ratio (INR) levels should be reversed to minimize hematoma enlargement, yet mode, timing, and extent of INR reversal are unclear. <ref type="bibr" target="#b4">3,</ref><ref type="bibr" target="#b10">9,</ref><ref type="bibr" target="#b11">10</ref></s><s>Valid data on safety and clinical benefit of OAC resumption are missing and remain to be established. <ref type="bibr" target="#b12">11</ref></s><s>his study investigated (1) the relationship between anticoagulation reversal and blood pressure with hematoma enlargement and (2) the association of restarting anticoagulation with incidence of hemorrhagic and ischemic complications with outcomes among patients with OAC-ICH.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>We chose a retrospective observational study design, and 19 tertiary care centers across Germany participated (7 university hospitals and 12 university-affiliated community hospitals; eFigure 1 in the Supplement).</s><s>We collected data from all consecutive adult patients with spontaneous ICH (International Statistical Classification of Diseases, Tenth Revision coding: I61.xx) related to anticoagulation admitted to neurological departments between the years 2006 and 2010 with a 1-year follow-up period ending in January 2012.</s><s>Specifically, the definition of OAC-ICH required effective use of vitamin K antagonists with an INR value of greater than 1.5 on hospital admission. <ref type="bibr" target="#b13">12</ref></s><s>We excluded ICH patients with secondary etiologies, ie, ICH related to trauma, tumor, arteriovenous malformation, aneurysmal subarachnoid hemorrhage, acute thrombolysis, or other coagulopathies.</s><s>Informed consent was obtained from all patients, legal representatives, or closest relatives.</s><s>Institutional review boards of all participating centers approved the study based on the central vote from the ethics committee at the University of Erlangen-Nuremberg.</s><s>The study was titled RETRACE (German-wide Multicenter Analysis of Oral Anticoagulationassociated Intracerebral Hemorrhage) and was conducted on behalf of IGNITE (Initiative of German Neurointensive Trial Engagement).</s><s>Figure <ref type="figure" target="#fig_0">1</ref> provides an overview of our 3-tiered analyses.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data Acquisition</head><p><s>We extracted data on demographics, prior comorbidities, inhospital parameters, and laboratory data through review of patients' medical records and institutional prospective databases (see the eMethods in the Supplement for a detailed list of parameters and definitions).</s><s>Review of medical records and emergency protocols determined neurological status consisting of Glasgow Coma Scale (GCS), National Institutes of Health Stroke Scale (NIHSS), and ICH score.</s><s>The CHADS 2 and HAS-BLED were scored as appropriate. <ref type="bibr" target="#b14">13,</ref><ref type="bibr" target="#b15">14</ref></s><s>After the end of the study follow-up, we conducted retrospective data evaluation, which was controlled by repeated visits (≥2) of all participating centers.</s></p><p><s>We obtained follow-up data on mortality, functional outcome, long-term treatment, and complications by mailed questionnaires and-if not returned or incomplete-by semiquantitative telephone interviews.</s><s>Two scale-trained physicians, certified for data collection on disability and quality of life, performed the interviews.</s><s>In situations of missing contact information, a local registry office inquiry was carried out to complete outcome assessment.</s><s>Cross-checking of centralized data with existing local prospective stroke registries and rehabilitation facility reports ensured data integrity.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data Synthesis and Analysis</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hematoma Enlargement</head><p><s>We analyzed hematoma enlargement in relation to INR reversal and blood pressure.</s><s>Hematoma enlargement was defined as a relative parenchymal volume increase of more than 33% from initial to follow-up imaging. <ref type="bibr" target="#b16">15</ref></s><s>We used this conservative threshold, as used in various trials, <ref type="bibr">16,</ref><ref type="bibr">17</ref> to exclude falsepositive scoring due to technical variability in computed tomography imaging. <ref type="bibr" target="#b16">15</ref></s><s>We evaluated all available computed tomography and magnetic resonance imaging scans of each patient and calculated parenchymal ICH volume according to hematoma shape, as previously described (ABC/2 and ABC/3). <ref type="bibr">18,</ref><ref type="bibr">19</ref></s><s>hen comparing different imaging modalities, we used validated conversion models for precise volume calculation. <ref type="bibr">20</ref></s><s>Intraventricular hemorrhage was recorded and its extent scored by the Graeb score summation. <ref type="bibr">21</ref></s><s>e recorded all different agents and dosages used for INR reversal as well as timing and extent of achieved INR levels.</s><s>Reversal treatment consisted of prothrombin complex concentrates ([PCCs] 4-factor concentrate, containing coagulation factors II, VII, IX, and X as well as protein C and S), <ref type="bibr" target="#b17">22</ref> freshfrozen plasma (FFP), antithrombin, and intravenous vitamin K-eventually in combinations.</s><s>The first INR value obtained after initiation of reversal treatment is referred to as first INR monitoring after reversal throughout the article.</s><s>Specifically, we evaluated all available laboratory results of coagulation parameters for 72 hours after admission and chose laboratory accessioning times as data points for monitoring of serial INR values.</s><s>For accuracy of data on INR reversal, the initial laboratory parameters for transferred patients were retrieved from referring hospitals.</s><s>For the association of hematoma enlargement with blood pressure, we recorded mean arterial blood pressure and systolic and diastolic blood pressures in 4-hour intervals from admission for 24 hours.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>OAC Resumption</head><p><s>Among all patients surviving acute hospitalization, we compared patients who restarted anticoagulation (referred to as OAC resumption) with patients not receiving anticoagulation (referred to as no OAC resumption).</s><s>Specifically, antithrombotic therapy used exclusively vitamin K antagonists (there was no approval of thrombin and factor Xa inhibitors for stroke prevention in Germany before the end of 2011) or no oral anticoagulants (antiplatelet agents, low-dose heparins, or no pharmacological treatment).</s><s>For all patients, starting time point (in days) and mode of antithrombotic treatment were recorded.</s><s>Patients were counted as having resumed OAC at the time of restarted OAC or if they received active heparinization before OAC resumption.</s></p><p><s>Resumption analysis included noting during the 1-year follow-up any new ischemic events, classified as either cerebral (ischemic stroke including transient ischemic attacks) or non-cerebral.</s><s>The latter included peripheral arterial emboli in lungs, gastrointestinal organs, or extremities and myocardial infarction. <ref type="bibr" target="#b18">23</ref></s><s>Recurrent hemorrhagic events were recorded as either cerebral-parenchymal or extracranial bleedings.</s><s>Extracerebral hemorrhages included gastrointestinal, intraocular, and intramuscular hemorrhage and hematuria. <ref type="bibr" target="#b18">23</ref></s><s>Complications, either ischemic or hemorrhagic, were noted when requiring hospitalization.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Long-term Functional Outcome</head><p><s>Functional outcome was evaluated using the modified Rankin Scale (mRS) at discharge, 3 months (short-term), and 1 year (long-term).</s><s>We distinguished favorable functional outcome (mRS = 0-3) from unfavorable functional outcome (mRS = 4-6). <ref type="bibr" target="#b19">24</ref></s><s>For analysis of overall mortality, we censored patients who were alive at the end of the study period or recorded cause and time of death.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis</head><p><s>Analyses of hematoma enlargement used multivariable regression analysis to identify associated parameters, which were prioritized for consecutive analysis according to relative risk ratio (RR).</s><s>First, receiver operating characteristics determined the highest Youden index of the best INR cut point to prevent hematoma enlargement. <ref type="bibr" target="#b20">25</ref></s><s>Second, we assessed optimal timing of INR reversal by analyzing categorized frequency distributions over selected INR and time intervals.</s><s>We calculated an univariate logistic regression model using generalized estimating equations <ref type="bibr" target="#b21">26</ref> to examine the association of INR reversal with hematoma enlargement over time.</s><s>Generated odds ratio (OR) estimates for various time points after initiation of reversal treatment were weighted according to available patient data and smoothed by the method of moving averages to correct for overestimation. <ref type="bibr" target="#b23">27</ref></s><s>Third, we investigated associations of systolic blood pressure with hematoma enlargement.</s><s>We categorized blood pressure in 20-mm Hg intervals (range, &lt;120-≥180 mm Hg) assessed (at 4-hour intervals) from time of hospital admission for 24 hours.</s><s>To display the combined associations of timing and extent of INR reversal and systolic blood pressure with hematoma enlargement, we used multivariable regression analysis adjusting for associated covariates (forest plot adjusted for covariates).</s></p><p><s>Analyses of OAC resumption consisted of graphical displays comparing patients who restarted OAC vs no OAC for ischemic and hemorrhagic events of the entire cohort.</s><s>Further analyses of OAC resumption were solely based on patients with atrial fibrillation.</s><s>To minimize confounding by indication, we performed propensity score matching using the balanced, parallel, variable ratio (1:n) nearest-neighbor approach. <ref type="bibr">28</ref></s><s>he propensity score was calculated from parameters showing statistical associations (P &lt; .10)</s><s>with OAC resumption.</s><s>Propensity-matched survival, displayed using the Kaplan-Meier method, was compared using log-rank, Breslow, and Tarone-Ware tests.</s><s>Crude event and incidence rates (per 100 patientyears) for new ischemic and recurrent hemorrhagic strokes were calculated for all individuals and their total number of days receiving target therapy (OAC vs no OAC) until 1-year follow-up.</s><s>To assess hazard ratios (HRs) for patients who restarted OAC for long-term mortality, we performed unadjusted and adjusted Cox regression analyses for the propensitymatched cohort of patients with atrial fibrillation; variables met assumption of proportionality. <ref type="bibr">28</ref></s><s>o identify parameters independently associated with functional long-term outcome, we calculated 3 log-binomial regression models: to describe improvement to favorable outcome for patients discharged with mRS of 4 and 5 and to display associations with unfavorable functional outcome for both the unmatched entire cohort as well as for the propensitymatched atrial fibrillation cohort.</s></p><p><s>For outcome analyses, we considered multiple imputation analyses calculated with all parameters available, ie, baseline characteristics, neurological status, imaging, in-hospital measures, and follow-up measures.</s><s>Nevertheless, after careful evaluation of missing and auxiliary data for multiple imputation analyses, we decided to conduct complete case analyses for OAC resumption and long-term outcome. <ref type="bibr" target="#b24">29</ref></s><s>r statistical analyses, we used SPSS version 20.0 and R version 2.12.0.</s><s>Statistical tests were 2-sided, and the significance level was set at α = .05</s><s>and consequently corrected for multiple comparisons by the Bonferroni method (eMethods in the Supplement).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Our study cohort consisted of 1176 patients with a complete primary data set.</s><s>The study cohort was selected from screening of 10 208 consecutive patients with ICH, of whom 1322 patients had OAC-ICH (period prevalence rate of 13.0%).</s><s>Details about the excluded patients (n = 146) are provided in Figure <ref type="figure" target="#fig_0">1</ref>.</s><s>Patients with OAC-ICH had a mean (SD) age of 74.1 (9.2) years, a median initial ICH volume of 19.3 cm 3 (interquartile range [IQR],6.9-52.8),</s><s>and a median INR level at time of hospital admission of 2.77 (IQR, 2.28-3.50).</s><s>Based on the number of patients and their epidemiological, neurological, and radiological profile (eTable 1 in the Supplement), our cohort was representative of patients with OAC-ICH. <ref type="bibr" target="#b12">11,</ref><ref type="bibr" target="#b13">12,</ref><ref type="bibr" target="#b25">30</ref></s><s>matoma Enlargement A total of 853 patients were eligible for analysis of hematoma enlargement (Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>Hematoma enlargement occurred in 307 of 853 patients (36.0%), with a median volume increase of 14.0 cm 3 (IQR, 4.7-36.8),</s><s>and secondary intraventricular hemorrhage in 76 of 307 patients (24.8%) (Table <ref type="table" target="#tab_1">1</ref>).</s><s>Hematoma enlargement rates were time-dependent and occurred more often in patients admitted earlier (median split onset to initial imaging; hematoma enlargement in 137/271 [50.6%] with early imaging [&lt;130 minutes] vs 95/278 [34.2%] with late imaging [≥130 min]; P &lt; .001).</s><s>When comparing patients with and without hematoma enlargement, there was no difference with respect to initial INR or agents used for its reversal.</s><s>We noted that PCCs reversed elevated INR levels to a greater extent (absolute median INR reversal using PCCs, 1.45 [IQR, 0.97-2.10]</s><s>vs FFP, 0.36 [IQR, 0.04-0.86];</s><s>P &lt; .001);</s><s>however, sample size (of patients with FFP only) was too small to draw firm conclusions regarding efficacy (Table <ref type="table" target="#tab_3">2</ref>).</s><s>Multivariable adjustments showed that shorter duration from symptom onset to imaging (RR, 2.284; 95% CI, 1.445-2.949;</s><s>P &lt; .001),</s><s>longer duration from diagnosis until treatment (RR, 1.559; 95% CI, 1.142-2.130;</s><s>P = .005),</s><s>deep ICH location (RR, 1.389; 95% CI, 1.012-1.905;</s><s>P = .04),</s><s>INR levels at first INR monitoring after reversal (RR, 2.294; 95% CI, 1.282-4.098;</s><s>P = .005),</s><s>systolic blood pressure at 4 hours (RR, 1.007; 95% CI, 1.002-1.014;</s><s>P = .02),</s><s>and history of coronary artery disease (RR, 1.531; 95% CI, 1.018-2.092;</s><s>P = .007)</s><s>were associated with hematoma enlargement (eTable 2 in the Supplement).</s><s>Hence, there were 3 parameters susceptible to modification: time until initiation of INR reversal, extent of INR reversal, and systolic blood pressure.</s></p><p><s>We used 2 approaches to identify the "optimal" timing and extent of INR reversal.</s><s>First, receiver operating characteristics analysis provided an INR value less than 1.3 with the strongest positive association to prevent hematoma enlargement (area under the curve, 0.636; 95% CI, 0.596-0.676;</s><s>P &lt; .001;</s><s><ref type="figure">2</ref>). <ref type="bibr" target="#b21">26</ref></s><s>Reduced hematoma enlargement was observed until 4 hours and 13 minutes (95% CI intercepts 1) with an unadjusted pooled OR of 0.37 (95% CI, 0.24-0.67;</s><s>P &lt; .001)</s><s>(Figure <ref type="figure">2</ref>).</s><s>We did not observe an additional benefit of reaching INR less than 1.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>OAC Resumption</head><p><s>Complete 1-year follow-up data were available for 719 patients discharged alive.</s><s>We excluded a total of 93 patients (81 patients had missing follow-up data and 12 withdrew consent) and restricted all outcome analyses to patients with complete data at 1-year follow-up (Figure <ref type="figure" target="#fig_0">1</ref>).</s><s><ref type="figure">4</ref>).</s><s>Atrial fibrillation is the major indication for anticoagulation, clinically of increasing relevance, and patients with atrial fibrillation represented the largest subgroup (n = 566) within our study population.</s><s>Thus, we based all further analyses of OAC resumption on patients with atrial fibrillation.</s><s>Within this subgroup, patients who restarted OAC showed a significantly decreased mortality (OAC: 9/110 [8.2%] vs no OAC: 171/456 [37.5%];</s><s>P &lt; .001)</s><s>and a reduced rate of ischemic complications (OAC: 6/110 [5.5%] vs no OAC: 68/456 [14.9%];</s><s>P = .008),</s><s>and rates of hemorrhagic complications were not different (OAC: 8/110 [7.3%] vs no OAC: 26/456 [5.7%]; P = .53)</s><s>(eFigure 2 in the Supplement).</s><s>Furthermore, we noticed significant differences in baseline characteristics.</s><s>Specifically, patients who resumed OAC were significantly younger and less severely affected at time of admission and showed superior functional status at time of discharge (eTable 6 in the Supplement).</s></p><p><s>To minimize confounding, we carried out propensity score matching for factors showing a statistical association with resumption status.</s><s>The matching resulted in 2 evenly balanced cohorts of patients with atrial fibrillation (range of standard-ized mean differences, 0.01-0.07)</s><s>(eTable 7 in the Supplement).</s><s>When comparing stroke incidence of the matched cohort, we noted a significantly decreased rate of cerebral infarctions (incidence rate per 100 patient-years) for patients who restarted OAC within this matched analysis (OAC: 3.9/ 100 patient-years [95% CI, 1.9-5.8]</s><s>vs no OAC: 12.7/100 patientyears [95% CI, 6.5-19.1];</s><s>P = .02)</s><s>(eTable 8 in the Supplement).</s><s>Recurrent ICH occurred without a statistical difference between patients who restarted or did not restart OAC (OAC: 3.9/100 patient-years [95% CI, 1.9-5.8]</s><s>vs no OAC: 3.9/100 patient-years [95% CI, 2.2-5.7];</s><s>P = .92).</s><s>Mortality analyses of the matched cohort at 1 year showed that 9 of 108 restarted patients (8.3%) vs 47 of 153 patients without OAC (30.7%) had died (P &lt; .001)</s><s>(Figure <ref type="figure">5</ref>).</s><s>This large difference of more than 22% triggered a multivariable-adjusted Cox regression analysis for longterm mortality of the matched atrial fibrillation cohort.</s><s>Among patients who restarted OAC treatment, there was a significantly decreased HR for long-term mortality of 0.258 (95% CI, 0.125-0.534;</s><s>P &lt; .001)</s><s>(eTable 9 in the Supplement).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Long-term Functional Outcome</head><p><s>Investigation of long-term functional outcomes used the entire cohort (n = 1176), and mortality was 364 of 1176 (31.0%) at hospital discharge, 475 of 1102 (43.1%) at 3 months, and 608 of 1083 (56.1%) after 1 year (Figure <ref type="figure" target="#fig_2">6</ref>).</s><s>Of all deceased patients during follow-up, 224 of 244 patients (91.8%) were discharged with a functional status of 4 or 5 on the mRS, and of these poor-grade discharged patients, 224 of 511 died (43.8%).</s><s>Unfavorable functional outcome (mRS = 4-6) was observed in 928 of 1176 patients (78.9%) at time of discharge and decreased to 786 of 1083 patients (72.6%) at 1 year.</s><s>Hence, the proportion of patients reaching favorable functional outcome increased only by 6.3% during follow-up.</s></p><p><s>To identify factors in poor-grade survivors (mRS = 4-5) associated with long-term improvement (change to mRS = 0-3), we performed a multivariable analysis and identified the following independent parameters associated with lack of im-  To reduce possible confounding of these results, we calculated a multivariable model of the matched cohort in patients with atrial fibrillation to analyze functional outcome (eTable 13 in the Supplement).</s><s>Analogous to findings of the unmatched entire cohort, we noticed independent associations for ischemic and hemorrhagic stroke with unfavorable outcome (ischemic stroke 13/20 [65.0%] vs no ischemic stroke: 98/ 241 [40.7%];</s><s>RR, 1.432; 95% CI, 1.055-1.943;</s><s>P = .02</s><s>and hemorrhagic stroke: ICH: 8/9 [88.9%] vs no ICH: 103/252 [40.9%];</s><s>RR, 2.581; 95% CI, 1.708-3.900;</s><s>P &lt; .001),</s><s>whereas age, ICH volume, and intraventricular hemorrhage were no longer significantly associated.</s><s>In contrast, OAC resumption was independently related to a decreased risk of unfavorable outcome at 1 year (OAC: 30/108 [27.8%] vs no OAC: 91/153 [52.9%];</s><s>RR, 0.552; 95% CI, 0.394-0.775;</s><s>P = .001).</s><s>The propensity-matched and adjusted analyses provided results with reduced bias and confounding.</s><s>Hence, there was a decreased ischemic stroke incidence and decreased risk of experiencing unfavorable functional long-term outcomes among patients who restarted OAC therapy after OAC-ICH.</s></p><p><s>Comparing baseline characteristics of patients lost to follow-up with those of patients included for complete case analyses did not show a statistically significant difference regard-ing all evaluated parameters (eTable 14 in the Supplement).</s><s>A multiple imputation analysis (eTable 15) resulted in increasing incidences of both ischemic and hemorrhagic complications (introduction of 83 new events: 34 ischemic and 49 hemorrhagic) while mortality and functional outcome would paradoxically decrease at 1-year follow-up.</s><s>Thus, we conducted complete case analyses to evaluate associations of OAC resumption and long-term outcome.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The study represents the largest cohort of patients with OAC-ICH to date and reports 2 clinically valuable associations.</s><s>First, rates of hematoma enlargement were decreased in patients with INR values reversed below 1.3 within 4 hours of admission and systolic blood pressures of less than 160 mm Hg at 4 hours.</s><s>Second, rates of ischemic events were decreased among patients who restarted OAC without increased rates of bleeding complications.</s></p><p><s>The occurrence of hematoma enlargement is an established risk factor for poor outcome in both primary and OACassociated ICH. <ref type="bibr" target="#b7">6,</ref><ref type="bibr">17,</ref><ref type="bibr" target="#b19">24</ref></s><s>Pharmacological interventions targeting hemostasis or blood pressure lowering have been shown to prevent hematoma enlargement in primary ICH; however, the effects on clinical end points are uncertain. <ref type="bibr">16,</ref><ref type="bibr" target="#b28">32,</ref><ref type="bibr" target="#b30">33</ref></s><s>In OAC-ICH, the pathophysiological mechanism of hematoma enlargement is complex, 8 its occurrence protracted and mainly driven by altered coagulation. <ref type="bibr" target="#b7">6,</ref><ref type="bibr" target="#b8">7</ref></s><s>This difference from primary ICH constitutes a target for aggressive medical treatment to minimize hematoma enlargement and possibly affect outcome. <ref type="bibr" target="#b7">6,</ref><ref type="bibr" target="#b8">7</ref></s><s>lthough it seems warranted to prospectively investigate the optimal INR reversal and its influence on clinical end points after OAC-ICH, it appears unlikely that sufficiently powered randomized trials will be realized (including a trial of whether PCCs sustain their benefit as an easily available and timely treatment compared with FFP <ref type="bibr" target="#b31">34,</ref><ref type="bibr" target="#b32">35</ref> ).</s></p><p><s>The clinical risks and benefits of restarting anticoagulation after OAC-ICH remain intensely debated and were re- Distribution of functional outcome at discharge, 3 months, and 1 year using the modified Rankin Scale (mRS).</s><s>An mRS of 0 indicates no symptoms; mRS 1, no significant disability, able to carry out all activities prior to stroke, some symptoms; mRS 2, slight disability, unable to carry out all activities prior to stroke, able to look after own affairs; mRS 3, moderate disability, requiring help, walking with cane or walker but without assistance; mRS 4, moderately severe disability, unable to attend bodily needs and to walk without assistance; mRS 5, severe disability, bedridden, requiring constant nursing care and attention; and mRS 6, death.</s><s>cently revived by data from the CHIRONE study. <ref type="bibr" target="#b12">11</ref></s><s>Patients with ICH have an elevated risk for recurrent ICH, <ref type="bibr" target="#b34">36</ref> which may be increased by restarting OAC. <ref type="bibr" target="#b12">11</ref></s><s>However, our data strengthen previous findings that patients restarting OAC do not show greater risk for recurrent ICH. <ref type="bibr" target="#b25">30</ref> Based on a considerably high thromboembolic risk without OAC <ref type="bibr" target="#b13">12,</ref><ref type="bibr" target="#b35">37</ref> (CHADS 2 score ≥2 in 79% of our patients), the increased incidence rate of ischemic stroke observed with our propensity-matched analyses argue in favor of OAC resumption.</s><s>Only a randomized trial, at least using cluster randomization, will settle the question about which stroke type is clinically more significant: increased rates of ischemic stroke vs lower rates of recurrent, possibly more severe ICH. <ref type="bibr" target="#b12">11,</ref><ref type="bibr" target="#b13">12,</ref><ref type="bibr" target="#b25">30</ref></s><s>In this regard, the use of new anticoagulants may further decline risk of recurrent ICH and-given acceptable adherence rates-also the hesitation about resuming anticoagulation <ref type="bibr" target="#b36">38</ref> counterbalancing self-fulfilling outcome evolutions. <ref type="bibr" target="#b37">39</ref></s><s>he present study has several strengths, including a large sample size with 1-year follow-up data from 19 tertiary care centers.</s><s>Analyses exploited rigorous statistical means to correct for bias and confounding.</s><s>Nevertheless, some drawbacks limit the interpretation of our findings, the first its retrospective nature, which attenuated data quality.</s><s>With regards to the determination of hematoma volume and presence of hematoma enlargement, some imprecisions in exact volume assessment remain because the measurements were not computer-assisted.</s><s>The association of systolic blood pressure with hematoma enlargement may have been influenced by compensatory mechanisms to maintain cerebral perfusion pressure in a subset of patients. <ref type="bibr" target="#b38">40</ref></s><s>Moreover, blood pressure values were not assessed continuously, which left room for uncertainty between the obtained 4-hour intervals.</s></p><p><s>Comparable with recursive partitioning, our analyses of hematoma enlargement used sequential analyses, leaving room for arbitrariness of used subdivision-related cut points.</s><s>Hence, this statistical approach may only reflect the characteristics of this study population, which highlights the need for external validation of the reported results by independent populations.</s><s>With regards to our findings on long-term outcome as well as safety and efficacy of OAC resumption, missing data for patients lost to follow-up potentially biased results.</s><s>We favored complete-case analyses instead of multiple imputations as comprehensive and meaningful auxiliary may not have been fully assessed (eTable 14 and eTable 15 in the Supplement).</s><s>Large confidence intervals may reflect certain data instability.</s><s>We only included ischemic and hemorrhagic events leading to hospitalization and did not longitudinally balance the clinical importance of these events.</s><s>Although propensity matching minimized confounding by indication, residual bias of parameters not investigated as well as healthy cohort and center effects may not be fully excluded. <ref type="bibr">28</ref></s><s>Finally, long-term follow-up information may have been influenced by erroneously answered questionnaires affecting the validity of mRS estimation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>Among patients with OAC-associated ICH, reversal of INR below 1.3 within 4 hours and systolic blood pressure less than 160 mm Hg at 4 hours were associated with lower rates of hematoma enlargement, and resumption of anticoagulant therapy was associated with lower risk of ischemic events without increased bleeding complications.</s><s>These retrospective findings require replication and assessment in prospective studies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ARTICLE INFORMATION</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Flow Diagram of Participating Centers, Study Participants, and 3-Tiered Analyses</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure</head><label></label><figDesc><div><p><s>Figure 3. Adjusted Graphical Regression Analysis of Combined Associations of INR Reversal, Systolic Blood Pressure, and Timing With Hematoma Enlargement</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 6 .</head><label>6</label><figDesc><div><p><s>Figure 6.</s><s>Long-term Functional Outcome of the Entire Cohort</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Clinical Characteristics of Patients With and Without Hematoma Enlargement a</s></p></div></figDesc><table><row><cell></cell><cell>With Hematoma</cell><cell>Without Hematoma</cell><cell></cell></row><row><cell>Patients With Follow-up Imaging</cell><cell>Enlargement</cell><cell>Enlargement</cell><cell></cell></row><row><cell>(n = 853)</cell><cell>(n = 307)</cell><cell>(n = 546)</cell><cell>P Value</cell></row><row><cell>Age, mean (SD), y</cell><cell>72.8 (9.9)</cell><cell>74.1 (8.6)</cell><cell>.07</cell></row><row><cell>Female sex, No. (%)</cell><cell>107 (34.9)</cell><cell>216 (39.6)</cell><cell>.17</cell></row><row><cell>Prior comorbidities, No. (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Hypertension</cell><cell>273 (88.9)</cell><cell>462 (84.6)</cell><cell>.08</cell></row><row><cell>Diabetes mellitus</cell><cell>91 (29.6)</cell><cell>167 (30.6)</cell><cell>.78</cell></row><row><cell>Dyslipidemia</cell><cell>81 (26.4)</cell><cell>168 (30.8)</cell><cell>.18</cell></row><row><cell>Prior stroke</cell><cell>89 (29.0)</cell><cell>162 (29.7)</cell><cell>.84</cell></row><row><cell>Coronary artery disease</cell><cell>154 (50.2)</cell><cell>225 (41.2)</cell><cell>.01 b</cell></row><row><cell>Congestive heart failure</cell><cell>34 (11.1)</cell><cell>74 (13.6)</cell><cell>.30</cell></row><row><cell>Abnormal kidney function</cell><cell>80 (26.1)</cell><cell>153 (28.0)</cell><cell>.54</cell></row><row><cell>Abnormal liver function</cell><cell>6 (2.0)</cell><cell>11 (2.0)</cell><cell>.84</cell></row><row><cell>Antiplatelet medication</cell><cell>31 (10.1)</cell><cell>52 (9.5)</cell><cell>.79</cell></row><row><cell>OAC indications, No. (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Atrial fibrillation</cell><cell>235 (76.5)</cell><cell>429 (78.6)</cell><cell>.49</cell></row><row><cell>Mechanical heart valve</cell><cell>32 (10.4)</cell><cell>35 (6.4)</cell><cell>.04 b</cell></row><row><cell>Pulmonary embolism</cell><cell>11 (3.6)</cell><cell>26 (4.8)</cell><cell>.42</cell></row><row><cell>Deep vein thrombosis</cell><cell>12 (3.9)</cell><cell>22 (4.0)</cell><cell>.92</cell></row><row><cell>Other indications</cell><cell>17 (5.5)</cell><cell>34 (6.2)</cell><cell>.68</cell></row><row><cell>CHADS 2 score c</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean (SD)</cell><cell>2.5 (1.2)</cell><cell>2.6 (1.2)</cell><cell></cell></row><row><cell>Median (IQR)</cell><cell>2 (2-3)</cell><cell>2 (2-3)</cell><cell>.55</cell></row><row><cell>High risk (≥2), No. (%)</cell><cell>183 (77.8)</cell><cell>353 (82.3)</cell><cell>.17</cell></row><row><cell>HAS-BLED score d</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean (SD)</cell><cell>3.2 (1.1)</cell><cell>3.0 (1.1)</cell><cell></cell></row><row><cell>Median (IQR)</cell><cell>3 (2-4)</cell><cell>3 (2-4)</cell><cell>.28</cell></row><row><cell>High risk ( ≥3), No. (%)</cell><cell>166 (70.6)</cell><cell>297 (69.2)</cell><cell>.71</cell></row><row><cell>Admission status, median (IQR)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Glasgow Coma Scale e</cell><cell>14 (12-15)</cell><cell>14 (12-15)</cell><cell>.16</cell></row><row><cell>NIHSS f</cell><cell>14 (6-18)</cell><cell>9 (4-16)</cell><cell>&lt;.001</cell></row><row><cell>ICH score g</cell><cell>1 (0-2)</cell><cell>1 (0-2)</cell><cell>.75</cell></row><row><cell>Initial imaging</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Deep ICH, No. (%)</cell><cell>173 (56.4)</cell><cell>233 (42.7)</cell><cell>&lt;.001</cell></row><row><cell>Lobar ICH, No. (%)</cell><cell>95 (30.9)</cell><cell>229 (41.9)</cell><cell>.001 b</cell></row><row><cell>Cerebellar ICH, No. (%)</cell><cell>25 (8.1)</cell><cell>71 (13.0)</cell><cell>.03 b</cell></row><row><cell>Brainstem ICH, No. (%)</cell><cell>14 (4.6)</cell><cell>13 (2.4)</cell><cell>.08</cell></row><row><cell>Left hemisphere, No. (%)</cell><cell>146 (47.6)</cell><cell>275 (50.4)</cell><cell>.43</cell></row><row><cell>ICH volume, median (IQR), cm 3</cell><cell>13.5 (5.0-27.6)</cell><cell>12.1 (5.3-26.9)</cell><cell>.45</cell></row><row><cell>Intraventricular hemorrhage, No. (%)</cell><cell>94 (30.6)</cell><cell>190 (34.8)</cell><cell>.21</cell></row><row><cell>Graeb score, median (IQR) h</cell><cell>4 (2-6)</cell><cell>4 (2-7)</cell><cell>.95</cell></row><row><cell>Follow-up imaging</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Time to control CT, median (IQR), h</cell><cell>13 (5-25)</cell><cell>20 (9-31)</cell><cell>&lt;.001</cell></row><row><cell>ICH volume, median (IQR), cm 3</cell><cell>29.7 (12.0-72.5)</cell><cell>12.5 (5.2-27.2)</cell><cell>&lt;.001</cell></row><row><cell>ICH volume increase, median (IQR), cm 3</cell><cell>14.0 (4.7-36.8)</cell><cell>0.5 (0.1-1.8)</cell><cell>&lt;.001</cell></row><row><cell>New IVH, No. (%)</cell><cell>76 (24.8)</cell><cell>27 (4.9)</cell><cell>&lt;.001</cell></row><row><cell>Graeb score, median (IQR)</cell><cell>5 (3-8)</cell><cell>4 (2-6)</cell><cell>&lt;.001</cell></row><row><cell>Time windows, median (IQR), min</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Symptom onset to imaging</cell><cell>104 (70-179)</cell><cell>143 (87-266)</cell><cell>&lt;.001</cell></row><row><cell>Symptom onset to treatment</cell><cell>218 (150-349)</cell><cell>230 (144-420)</cell><cell>.35</cell></row><row><cell>Admission to treatment</cell><cell>117 (64-234)</cell><cell>103 (62-186)</cell><cell>.08</cell></row><row><cell>Diagnosis to treatment</cell><cell>95 (44-180)</cell><cell>70 (36-133)</cell><cell>.001</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(continued)</cell></row></table><note><p><s>sion: 43/217 [19.8%] vs INR ≥1.3 not within 4 hours: 264/636 [41.5%];</s><s>P &lt; .001)</s><s>(eTable 3 in the Supplement).</s><s>To investigate associations of optimal timing for INR reversal (&lt;1.3) with hematoma enlargement, we calculated an estimated OR model (Figure</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>2. Thus, our data indicate that INR reversal to values below 1.3 achieved within 4 hours was associated with fewest rates of hematoma enlargement.</s><s>The association of blood pressure with hematoma enlargement is shown in eTable 4 in the Supplement.</s><s>Systolic blood pressure values of 160 mm Hg or greater assessed 4 hours after admission showed increased rates of hematoma enlargement (&lt;160 mm Hg: 167/504 [33.1%] vs ≥160 mm Hg: 98/187 [52.4%];</s><s>P &lt; .001).</s><s>To investigate the additional importance of systolic Clinical Characteristics of Patients With and Without Hematoma Enlargement a (continued)</s></p></div></figDesc><table><row><cell cols="2">Treating Anticoagulation-Related Intracerebral Hemorrhage</cell><cell></cell><cell></cell><cell>Original Investigation Research</cell></row><row><cell></cell><cell>With Hematoma</cell><cell>Without Hematoma</cell><cell></cell><cell></cell></row><row><cell>Patients With Follow-up Imaging</cell><cell>Enlargement</cell><cell>Enlargement</cell><cell></cell><cell></cell></row><row><cell>(n = 853)</cell><cell>(n = 307)</cell><cell>(n = 546)</cell><cell>P Value</cell><cell></cell></row><row><cell>Mode of reversal treatment</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>PCC, median (IQR), IU</cell><cell>2000 (1200-2400)</cell><cell>2000 (1200-2400)</cell><cell>.53</cell><cell></cell></row><row><cell>PCC + vitamin K, No. (%)</cell><cell>192 (62.5)</cell><cell>359 (65.8)</cell><cell>.35</cell><cell></cell></row><row><cell>PCC only, No. (%)</cell><cell>42 (13.7)</cell><cell>57 (10.4)</cell><cell>.16</cell><cell></cell></row><row><cell>PCC + FFP + vitamin K, No. (%)</cell><cell>19 (6.2)</cell><cell>40 (7.3)</cell><cell>.53</cell><cell></cell></row><row><cell>PCC + combinations, No. (%)</cell><cell>15 (4.9)</cell><cell>35 (6.4)</cell><cell>.36</cell><cell></cell></row><row><cell>FFP only, No. (%)</cell><cell>5 (1.6)</cell><cell>6 (1.1)</cell><cell>.54</cell><cell></cell></row><row><cell>Vitamin K only, No. (%)</cell><cell>34 (11.1)</cell><cell>49 (9.0)</cell><cell>.31</cell><cell></cell></row><row><cell>Initial coagulation parameters, median (IQR)</cell><cell></cell><cell></cell><cell></cell><cell>Abbreviations: CT, computed</cell></row><row><cell>INR</cell><cell>2.80 (2.30-3.41)</cell><cell>2.68 (2.23-3.38)</cell><cell>.13</cell><cell>tomography; FFP, fresh-frozen</cell></row><row><cell>PTT, s Serial monitoring of coagulation parameters, median (IQR) INR after reversal i</cell><cell>43 (37-50) 1.38 (1.20-1.71)</cell><cell>41 (36-49) 1.27 (1.16-1.44)</cell><cell>.13 &lt;.001</cell><cell>plasma; ICH, intracerebral hemorrhage; INR, international normalized ratio; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; OAC, oral</cell></row><row><cell>PTT after reversal, s i</cell><cell>34 (31-39)</cell><cell>33 (30-38)</cell><cell>.32</cell><cell>anticoagulation; PCC, prothrombin</cell></row><row><cell>INR at 24 h INR at 48 h INR at 72 h</cell><cell>1.30 (1.20-1.44) 1.23 (1.14-1.38) 1.23 (1.13-1.40)</cell><cell>1.23 (1.13-1.48) 1.20 (1.10-1.31) 1.19 (1.10-1.30)</cell><cell>&lt;.001 .002 b .001 b</cell><cell>complex concentrates; PTT, partial thromboplastin time. a Hematoma enlargement was defined as volume increase &gt;33% on</cell></row><row><cell>Laboratory values, median (IQR)</cell><cell></cell><cell></cell><cell></cell><cell>follow-up imaging.</cell></row><row><cell>Hemoglobin, g/L</cell><cell>137 (120-149)</cell><cell>140 (125-153)</cell><cell>.02 b</cell><cell>b Not significant after Bonferroni</cell></row><row><cell>Hematocrit Thrombocytes, 10 9 /L Leukocytes, 10 9 /L</cell><cell>0.41 (0.37-0.44) 199 (166-241) 8.1 (6.2-9.7)</cell><cell>0.42 (0.38-0.45) 202 (170-248) 8.5 (6.8-10.2)</cell><cell>.11 .25 .01 b</cell><cell>correction (corrected significance level P &lt; .00104). c CHADS 2 score range, 0-6, from low to high risk of thromboembolism.</cell></row><row><cell>Blood pressure, mean (SD), mm Hg</cell><cell></cell><cell></cell><cell></cell><cell>d HAS-BLED score range, 0-9, from</cell></row><row><cell>Admission systolic</cell><cell>172 (31)</cell><cell>168 (30)</cell><cell>.12</cell><cell>low to high risk of bleeding</cell></row><row><cell>Admission mean arterial Admission diastolic</cell><cell>119 (21) 92 (18)</cell><cell>116 (21) 91 (18)</cell><cell>.09 .30</cell><cell>complication under OAC. e Glasgow Coma Scale range, 3-15, from deep coma to alert.</cell></row><row><cell>4-h Systolic</cell><cell>153 (28)</cell><cell>139 (23)</cell><cell>&lt;.001</cell><cell>f NIHSS range, 0-40, from no deficit</cell></row><row><cell>4-h Mean arterial</cell><cell>103 (22)</cell><cell>93 (17)</cell><cell>.01 b</cell><cell>to severe neurological deficit</cell></row><row><cell>4-h Diastolic 8-h Systolic</cell><cell>79 (19) 142 (25)</cell><cell>71 (15) 138 (22)</cell><cell>.002 b .17</cell><cell>(42 = maximum sum, but for comatose patient, ataxia is not scored).</cell></row><row><cell>8-h Mean arterial</cell><cell>94 (18)</cell><cell>91 (16)</cell><cell>.27</cell><cell>g ICH score range, 0-6, from low to</cell></row><row><cell>8-h Diastolic</cell><cell>71 (16)</cell><cell>68 (15)</cell><cell>.06</cell><cell>high risk of mortality.</cell></row><row><cell>12-h Systolic</cell><cell>141 (24)</cell><cell>138 (23)</cell><cell>.37</cell><cell>h Graeb score of ventricular</cell></row><row><cell>12-h Mean arterial</cell><cell>93 (18)</cell><cell>92 (16)</cell><cell>.93</cell><cell>involvement range, 0-12, from no intraventricular blood to tamponade</cell></row><row><cell>12-h Diastolic</cell><cell>70 (16)</cell><cell>69 (15)</cell><cell>.32</cell><cell>of all ventricles.</cell></row><row><cell>16-h Systolic</cell><cell>142 (23)</cell><cell>140 (22)</cell><cell>.50</cell><cell>i Indicates first value of serial</cell></row><row><cell>16-h Mean arterial</cell><cell>94 (15)</cell><cell>93 (16)</cell><cell>.61</cell><cell>monitoring of coagulation</cell></row><row><cell>16-h Diastolic</cell><cell>71 (17)</cell><cell>70 (15)</cell><cell>.57</cell><cell>parameters after initiation of reversal treatment.</cell></row><row><cell>jama.com</cell><cell></cell><cell cols="3">(Reprinted) JAMA February 24, 2015 Volume 313, Number 8</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Subgroup Analysis for Mode of Reversal Treatment, Comparing Fresh-Frozen Plasma vs Prothrombin Complex Concentrates</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="4">Prothrombin Complex</cell></row><row><cell></cell><cell cols="3">Fresh-Frozen Plasma</cell><cell></cell><cell cols="2">Concentrates</cell></row><row><cell>Initial coagulation parameters</cell><cell></cell><cell cols="2">(n = 11)</cell><cell></cell><cell cols="2">(n = 650)</cell><cell>P Value</cell><cell>Abbreviations: INR, international normalized ratio, IQR, interquartile</cell></row><row><cell>INR, median (IQR)</cell><cell cols="3">2.20 (1.84-3.45)</cell><cell></cell><cell cols="2">2.79 (2.30-3.45)</cell><cell>.11</cell><cell>range; PTT, partial thromboplastin</cell></row><row><cell>PTT, median (IQR), s</cell><cell cols="3">40 (34-49)</cell><cell></cell><cell cols="2">42 (36-49)</cell><cell>.66</cell><cell>time.</cell></row><row><cell>First monitoring after reversal a INR, median (IQR)</cell><cell cols="3">1.66 (1.20-2.42)</cell><cell></cell><cell cols="2">1.27 (1.15-1.44)</cell><cell>.01 b</cell><cell>a Indicates first value of serial monitoring of coagulation parameters after initiation of</cell></row><row><cell>PTT, median (IQR), s</cell><cell cols="3">34 (32-38)</cell><cell></cell><cell cols="2">33 (30-37)</cell><cell>.35</cell><cell>reversal treatment.</cell></row><row><cell>Absolute INR reversal, median (IQR)</cell><cell cols="3">0.36 (0.04-0.86)</cell><cell></cell><cell cols="2">1.45 (0.97-2.10)</cell><cell>&lt;.001</cell></row><row><cell>Hematoma enlargement, No. (%)</cell><cell></cell><cell cols="2">5 (45.4)</cell><cell></cell><cell cols="2">236 (36.3)</cell><cell>.75</cell></row><row><cell></cell><cell>10</cell><cell cols="4">Hematoma enlargement prevented</cell><cell cols="2">Hematoma enlargement not prevented</cell></row><row><cell></cell><cell></cell><cell cols="4">with INR reversal to &lt;1.3</cell><cell></cell><cell>with INR reversal to &lt;1.3</cell></row><row><cell></cell><cell cols="4">Mean of 5 OR estimates per hour</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>95% CI</cell></row><row><cell>Odds Ratio</cell><cell>1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>5% CI</cell></row><row><cell></cell><cell>0.1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">1</cell><cell>2</cell><cell cols="2">3</cell><cell>4</cell><cell>5</cell><cell>6</cell><cell>7</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">Time Since Admission, h</cell></row><row><cell cols="3">Patients with hematoma enlargement,</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">shown as No./No. achieving INR (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>INR &lt;1.3</cell><cell cols="2">5/26 (19.2)</cell><cell>9/51 (17.6)</cell><cell cols="2">14/73 (19.2)</cell><cell>15/67 (22.4)</cell><cell>7/22 (31.8)</cell><cell>9/25 (36.0)</cell></row><row><cell>INR ≥1.3</cell><cell cols="2">6/17 (35.3)</cell><cell>11/30 (36.7)</cell><cell cols="2">25/64 (39.1)</cell><cell>27/64 (42.2)</cell><cell>11/28 (39.3)</cell><cell>13/29 (44.8)</cell></row><row><cell cols="4">Logistic regression model using generalized estimating equations to visualize</cell><cell></cell><cell cols="3">estimate at hour 1 represents a mean of the 5 included OR estimates at 00:36</cell></row><row><cell cols="4">the association of "optimal" international normalized ratio (INR) reversal (INR</cell><cell></cell><cell cols="3">hours (ie, all data 00:24-00:48), at 00:48 hours (ie, all data 00:36-01:00), at</cell></row><row><cell cols="4">&lt;1.3 vs INR Ն1.3 on first monitoring after reversal treatment) with hematoma</cell><cell></cell><cell cols="3">01:00 hours (ie, all data 00:48-01:12), at 01:12 hours (ie, all data 01:00-01:24),</cell></row><row><cell cols="5">enlargement over time. Hematoma enlargement was defined as relative volume</cell><cell cols="3">and at 01.24 hours (ie, all data 01:12-01:36). Each OR was weighted according to</cell></row></table><note><p><s>27Not significant after Bonferroni correction (corrected significance level P &lt; .00104).Figure 2. Association of Timing and Extent of INR ReversalWith Hematoma Enlargement increase of &gt;33% on follow-up imaging.The thick blue line represents a regression of odds ratio (OR) estimates generated every 12 min.Each OR estimate included available data covering ±12 minutes (actual data started at 00:24 hours); ie, the first OR estimate was calculated at 00:36 hours and included all available data from 00:24-00:48 hours.Data markers represent the mean of those 5 OR estimates that encompassed full hours; eg, the OR available data points within each time interval, and generation included the method of moving averages (binning of 5 subsequent ORs).27The vertical dashed line indicates the last significant OR estimate at 04:12 hours.</s><s>We only included those patients for analysis (n = 496) for whom the first INR value obtained after initiation of reversal treatment was available within the assessed time frame (00:24-06:36 hours).</s><s>Error bars indicate 95% CIs.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head></head><label></label><figDesc><div><p><s>3. Adjusted Graphical Regression Analysis of Combined Associations of INR Reversal, Systolic Blood Pressure, and Timing With Hematoma EnlargementMultivariable model for the combined associations, ie, extent and timing of international normalized ratio (INR) reversal and systolic blood pressure (BP), with hematoma enlargement.Hematoma enlargement was defined as relative volume increase of &gt;33% on follow-up imaging.Adjustments consisted of all nonmodifiable parameters associated with hematoma enlargement, ie, time from symptom onset to imaging, deep intracerebral hemorrhage location, National Institutes of Health Stroke Scale score, and comorbidity (eTable 2 in the Supplement).OR indicates odds ratio.Figure 4. Crude Incidence Rates of Ischemic and Hemorrhagic Complications During 1-Year Follow-up in Patients With and Without OAC Resumption Figure 5. Kaplan-Meier Survival Rates of Patients With Atrial Fibrillation With and Without OAC Resumption</s></p></div></figDesc><table><row><cell>Treating Anticoagulation-Related Intracerebral Hemorrhage</cell><cell>Original Investigation Research</cell></row><row><cell cols="2">P Value &lt;.001 &lt;.001 &lt;.001 0.994; P = .04), and new ischemic stroke (RR: 0.113; 95% CI, Favors Prevention of Hematoma Enlargement Does Not Favor Prevention of Hematoma Enlargement 10 1.0 0.1 OR (95% CI) OR (95% CI) 0.37 (0.26-0.59) 0.27 (0.15-0.43) 0.17 (0.11-0.33) 0.016-0.792; P = .03). Only higher hemoglobin levels at time of admission was significantly associated with functional im-12 16 20 24 28 32 36 40 44 48 52 No. of Patients Patients With Hematoma Enlargement, No. (%) 432 116 (26.9) 421 191 (45.4) 217 43 (19.8) 636 264 (41.5) and systolic BP &lt;160 mm Hg within 4 hours INR &lt;1.3 Achieved Did not achieve INR &lt;1.3 within 4 hours Achieved Did not achieve INR &lt;1.3 within 4 hours 193 35 (18.1) Achieved 498 220 (44.2) Did not achieve jama.com 0.993; P = .01), neurological status (NIHSS, RR: 0.956; 95% CI, 0.922-0.992; P = .02), ICH volume (RR: 0.576; 95% CI, 0.334-25 20 15 10 5 0 0 Incidence, % Time, wk 4 8 Ischemic events A No OAC resumption OAC resumption 25 20 15 10 5 547 172 Incidence, % 518 172 481 170 445 170 416 169 399 168 389 166 375 166 362 165 354 163 343 161 336 161 322 159 316 157 Hemorrhagic events B χ² P &lt;.001 No OAC resumption OAC resumption No OAC resumption OAC resumption χ² P = .48 Incidence rates of (A) new ischemic vs those who did not restart OAC. Analyses were based on all patients with complete 1-year follow-up data. No. of patients OAC resumption No OAC resumption 100 80 60 40 20 0 108 153 0 Survival, % Time Since Index ICH, wk 108 146 4 106 139 8 106 134 12 105 130 16 105 125 20 103 121 24 103 119 28 102 117 32 102 117 36 101 114 40 101 111 44 101 108 48 99 106 52 No OAC resumption OAC resumption Log-rank P &lt;.001 Breslow P &lt;.001 Tarone-Ware P &lt;.001 Kaplan-Meier survival curves of the propensity-matched cohort (which included only patients who were discharged alive) comparing patients with atrial fibrillation who restarted oral anticoagulation (OAC) vs those who did not restart OAC. Survival is presented from index intracerebral hemorrhage (ICH) until 1-year follow-up and analyzed by log-rank, Breslow, and Tarone-Ware testing. provement (RR: 1.197; 95% CI, 1.070-1.338; P = .002) (eTable 10 in the Supplement). Analysis of unfavorable long-term outcome showed asso-ciations for parameters similar to those established for spon-taneous ICH (eTable 11 and eTable 12 in the Supplement). 31 When investigating independent associations of unfavorable functional long-term outcome in the unmatched cohort, we noted an increased risk for both new ischemic stroke and re-current ICH (ischemic stroke: 45/63 [71.4%] vs no ischemic stroke: 384/656 [58.5%]; RR, 1.554; 95% CI, 1.101-2.419; P = .02; recurrent ICH: 27/30 [90.0%] vs no ICH: 394/689 [57.2%]; RR, 2.884; 95% CI, 1.203-8.636; P = .03). The only parameter sig-nificantly associated with a decreased RR for unfavorable func-tional long-term outcome was OAC resumption (OAC: 54/172 [31.4%] vs no OAC: 367/547 [67.1%]; RR, 0.330; 95% CI, 0.205-(Reprinted) JAMA February 24, 2015 Volume 313, Number 8 provement during follow-up: age (RR, 0.968; 95% CI, 0.945-No. of patients 0 0 restarted oral anticoagulation (OAC) Time, wk 4 8 12 16 20 24 28 32 36 40 44 48 comparing all surviving patients who 52 and (B) hemorrhagic events 0.531; P &lt; .001).</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">JAMA February 24, 2015 Volume 313, Number 8 (Reprinted) jama.com Copyright 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 05/17/2022</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Copyright 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 05/17/2022</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Role of the Funder/Sponsor: The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Group Information:</head><p><s>The German-wide Multicenter Analysis of Oral Anticoagulation-associated Intracerebral Hemorrhage (RETRACE) investigators performed this study on behalf of IGNITE (Initiative of German Neurointensive Trial Engagement).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional Contributions:</head><p><s>We thank Inken Martin, MD, PhD (Victor Chang Cardiac Research Institute, Sydney, Australia), and Jochen K. Lennerz, MD, PhD (Massachusetts General Hospital, Harvard Medical School, Boston), for critically proofreading the manuscript, as well as Martin Radespiel-Tröger, MD, PhD (Population Based Cancer Registry Bavaria, University Hospital Erlangen, Germany), for helping with statistical analyses.</s><s>We thank Antje Milker, MD, and Petra Burkhard, PhD (University of Erlangen, Germany), as well as Ralph Werner, MD (Koblenz, Germany), for helping with logistics and data monitoring and Olaf Bergmann, MD, PhD (Karolinska Institute, Stockholm, Sweden), for valuable discussions.</s><s>None of these persons received any compensation for their contributions.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Department of Neurology</title>
		<author>
			<persName><forename type="first">Asklepios Klinik St</forename><surname>Georg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Institute of Clinical Epidemiology and Biometry</title>
				<meeting><address><addrLine>Hamburg, Germany (Terborg, Trostdorf; Stuttgart, Germany (Bäzner, Roth; Koblenz, Germany (Wöhrle, Keller; Dortmund, Germany (Schwarz, Reimann; Würzburg, Germany (Volkmann, Müllges, Kraft; Würzburg, Germany (Kraft; Leipzig, Germany (Classen, Hobohm</addrLine></address></meeting>
		<imprint/>
		<respStmt>
			<orgName>Department of Neurology, Community Hospital Klinikum Stuttgart ; Department of Neurology, Community Hospital Klinikum Koblenz ; Department of Neurology, University of Würzburg ; University of Würzburg ; Department of Neurology, University of Leipzig</orgName>
		</respStmt>
	</monogr>
	<note>Comprehensive Heart Failure Center</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Community Hospital Fulda</title>
		<imprint/>
		<respStmt>
			<orgName>Department of Neurology, University of Dresden ; Department of Neurology, University of Cologne ; Department of Neurology, University of Jena ; Department of Neurology, Community Hospital Nuremberg</orgName>
		</respStmt>
	</monogr>
	<note>Department of Neurology</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study</title>
		<author>
			<persName><forename type="first">Reichmann</forename><surname>Milewski</surname></persName>
		</author>
		<author>
			<persName><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><surname>Schimmel</surname></persName>
		</author>
		<author>
			<persName><surname>Fink</surname></persName>
		</author>
		<author>
			<persName><surname>Dohmen</surname></persName>
		</author>
		<author>
			<persName><surname>Stetefeld</surname></persName>
		</author>
		<author>
			<persName><surname>Witte</surname></persName>
		</author>
		<author>
			<persName><surname>Günther</surname></persName>
		</author>
		<author>
			<persName><surname>Neumann-Haefelin</surname></persName>
		</author>
		<author>
			<persName><surname>Racs</surname></persName>
		</author>
		<author>
			<persName><surname>Nueckel</surname></persName>
		</author>
		<author>
			<persName><surname>Erbguth</surname></persName>
		</author>
		<author>
			<persName><surname>Kloska</surname></persName>
		</author>
		<author>
			<persName><surname>Doerfler</surname></persName>
		</author>
		<author>
			<persName><surname>Köhrmann</surname></persName>
		</author>
		<author>
			<persName><surname>Schwab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><surname>Huttner</surname></persName>
		</author>
		<author>
			<persName><surname>Kuramatsu</surname></persName>
		</author>
		<author>
			<persName><surname>Gerner</surname></persName>
		</author>
		<author>
			<persName><surname>Glahn</surname></persName>
		</author>
		<author>
			<persName><surname>Flechsenhar</surname></persName>
		</author>
		<author>
			<persName><surname>Neugebauer</surname></persName>
		</author>
		<author>
			<persName><surname>Jüttler</surname></persName>
		</author>
		<author>
			<persName><surname>Grau</surname></persName>
		</author>
		<author>
			<persName><surname>Palm</surname></persName>
		</author>
		<author>
			<persName><surname>Röther</surname></persName>
		</author>
		<author>
			<persName><surname>Michels</surname></persName>
		</author>
		<author>
			<persName><surname>Hamann</surname></persName>
		</author>
		<author>
			<persName><surname>Hüwel</surname></persName>
		</author>
		<author>
			<persName><surname>Barber</surname></persName>
		</author>
		<author>
			<persName><surname>Terborg</surname></persName>
		</author>
		<author>
			<persName><surname>Trostdorf</surname></persName>
		</author>
		<author>
			<persName><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><surname>Wöhrle</surname></persName>
		</author>
		<author>
			<persName><surname>Müllges</surname></persName>
		</author>
		<author>
			<persName><surname>Kraft</surname></persName>
		</author>
		<author>
			<persName><surname>Classen</surname></persName>
		</author>
		<author>
			<persName><surname>Hobohm</surname></persName>
		</author>
		<author>
			<persName><surname>Reichmann</surname></persName>
		</author>
		<author>
			<persName><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><surname>Schimmel</surname></persName>
		</author>
		<author>
			<persName><surname>Fink</surname></persName>
		</author>
		<author>
			<persName><surname>Dohmen</surname></persName>
		</author>
		<author>
			<persName><surname>Stetefeld</surname></persName>
		</author>
		<author>
			<persName><surname>Witte</surname></persName>
		</author>
		<author>
			<persName><surname>Neumann-Haefelin</surname></persName>
		</author>
		<author>
			<persName><surname>Racs</surname></persName>
		</author>
		<author>
			<persName><surname>Nueckel</surname></persName>
		</author>
		<author>
			<persName><surname>Kloska</surname></persName>
		</author>
		<author>
			<persName><surname>Doerfler</surname></persName>
		</author>
		<author>
			<persName><surname>Schwab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><surname>Huttner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Hylek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Statistical analysis: Kuramatsu, Schellinger, Huttner. Obtained funding: Kuramatsu, Huttner. Administrative, technical, or material support</title>
				<meeting><address><addrLine>Schellinger, Jüttler, Wöhrle, Classen, Horn, Erbguth, Schwab</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2001">2001</date>
			<biblScope unit="volume">285</biblScope>
			<biblScope unit="page" from="2370" to="2375" />
		</imprint>
	</monogr>
	<note>JAMA</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Contemporary trends of hospitalization for atrial fibrillation in the United States</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Deshmukh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pant</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="2371" to="2379" />
			<date type="published" when="2000">2000 through 2010. 2014</date>
		</imprint>
	</monogr>
	<note>: implications for healthcare planning</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy</title>
		<author>
			<persName><forename type="first">L</forename><surname>Masotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Napoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Godoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Stroke</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="228" to="240" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Hylek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Go</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">349</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1019" to="1026" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage</title>
		<author>
			<persName><forename type="first">J</forename><surname>Rosand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Eckman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Knudsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Singer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Greenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="880" to="884" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Flibotte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hagan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Donnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Greenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Rosand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1059" to="1064" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Warfarin use leads to larger intracerebral hematomas</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Flaherty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Haverbusch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="1084" to="1089" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Oral anticoagulant-associated intracerebral hemorrhage</title>
		<author>
			<persName><forename type="first">A</forename><surname>Cervera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Amaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chamorro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol</title>
		<imprint>
			<biblScope unit="volume">259</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="212" to="224" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">American Heart Association Stroke Council and Council on Cardiovascular Nursing. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Morgenstern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Hemphill</surname></persName>
		</author>
		<author>
			<persName><surname>Iii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stroke</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2108" to="2129" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage</title>
		<author>
			<persName><forename type="first">T</forename><surname>Steiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Al-Shahi</forename><surname>Salman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Beer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Stroke</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="840" to="855" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study</title>
		<author>
			<persName><forename type="first">D</forename><surname>Poli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Antonucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Dentali</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1020" to="1026" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Italian Federation of Anticoagulation Clinics (FCSA)</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Optimal timing of resumption of warfarin after intracranial hemorrhage</title>
		<author>
			<persName><forename type="first">A</forename><surname>Majeed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Holmström</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schulman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stroke</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2860" to="2866" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Gage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Waterman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Shannon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boechler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Rich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Radford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">285</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="2864" to="2870" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey</title>
		<author>
			<persName><forename type="first">R</forename><surname>Pisters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Lane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nieuwlaat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>De Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Crijns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Lip</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1093" to="1100" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Early hemorrhage growth in patients with intracerebral hemorrhage</title>
		<author>
			<persName><forename type="first">T</forename><surname>Brott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Broderick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kothari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stroke</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study</title>
		<author>
			<persName><forename type="first">R</forename><surname>Sarode</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Milling</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Refaai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1234" to="1243" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Connolly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Ezekowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yusuf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1139" to="1151" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Predictors of outcome in warfarin-related intracerebral hemorrhage</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Zubkov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Mandrekar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">O</forename><surname>Claassen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Manno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Wijdicks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Rabinstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1320" to="1325" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Zweig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Campbell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="561" to="577" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<author>
			<persName><forename type="first">W</forename><surname>Hacke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Donnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fieschi</surname></persName>
		</author>
		<title level="m">ATLANTIS Trials Investigators; ECASS Trials Investigators</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials</title>
	</analytic>
	<monogr>
		<title level="m">NINDS rt-PA Study Group Investigators</title>
				<imprint>
			<date type="published" when="2004">2004</date>
			<biblScope unit="volume">363</biblScope>
			<biblScope unit="page" from="768" to="774" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Risk-adjusted survival time monitoring with an updating exponentially weighted moving average (EWMA) control chart</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Steiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>; Rassen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Shelat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Myers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Glynn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Rothman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schneeweiss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacoepidemiol Drug Saf</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="69" to="80" />
			<date type="published" when="2010">2010. 2012</date>
		</imprint>
	</monogr>
	<note>Stat Med. suppl</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Dealing with missing outcome data in randomized trials and observational studies</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Groenwold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Donders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Roes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Harrell</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Moons</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">175</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="210" to="217" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">D</forename><surname>Yung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Kapral</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Asllani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study</title>
	</analytic>
	<monogr>
		<title level="m">Registry of the Canadian Stroke Network</title>
				<imprint>
			<date type="published" when="2012">2012</date>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="33" to="39" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Spontaneous intracerebral hemorrhage</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Qureshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tuhrim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Broderick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Batjer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hondo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Hanley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">344</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="1450" to="1460" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Heeley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage</title>
	</analytic>
	<monogr>
		<title level="m">INTERACT2 Investigators</title>
				<imprint>
			<date type="published" when="2013">2013</date>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="2355" to="2365" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Mayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Brun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Begtrup</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">FAST Trial Investigators</title>
				<imprint>
			<date type="published" when="2008">2008</date>
			<biblScope unit="volume">358</biblScope>
			<biblScope unit="page" from="2127" to="2137" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Huttner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Schellinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hartmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stroke</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1465" to="1470" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Holbrook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schulman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Witt</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis</title>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="e152S" to="e184" />
			<date type="published" when="2012">2012</date>
			<publisher>American College of Chest Physicians</publisher>
		</imprint>
	</monogr>
	<note>American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. suppl</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Hart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Benavente</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Pearce</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="773" to="777" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation</title>
		<author>
			<persName><forename type="first">Avgil</forename><surname>Tsadok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jackevicius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Rahme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Humphries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Behlouli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Pilote</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">307</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="1952" to="1958" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation</title>
		<author>
			<persName><forename type="first">S</forename><surname>Chatterjee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sardar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Biondi-Zoccai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kumbhani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Neurol</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1486" to="1490" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Withdrawal of support in intracerebral hemorrhage may lead to self-fulfilling prophecies</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Baxter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Cohen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="766" to="772" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Monitoring the injured brain: ICP and CBF</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Steiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Andrews</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Anaesth</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="26" to="38" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
